Apogenix GmbH, of Heidelberg, Germany, said it achieved additional milestones under its deal with Canbridge Life Sciences Ltd., of Beijing, related to the implementation of the technology transfer necessary for the production of the CD95 ligand inhibitor APG101 at the Chinese production site.